期刊文献+

新型抗凝血多肽Hirulog-S的质量分析 被引量:3

Quality analysis of novel anticoagulant peptide Hirulog-S
原文传递
导出
摘要 目的:建立一种适用于新型抗凝血多肽Hirulog-S含量及杂质的分析方法,以及其水分和三氟乙酸(TFA)含量测定方法。方法:采用Zorbax Eclipse XDB-C18色谱柱(150 mm×4.6 mm,5μm),以含0.1%TFA的水为流动相A,含0.1%TFA的乙腈为流动相B,流速1.0 mL.min-1,检测波长214 nm,柱温25℃,测定样品中的含量及有关物质。采用卡尔菲休库仑滴定法测定水分,使用高效液相色谱法(HPLC)测其TFA含量。结果:在选定的色谱条件下,Hirulog-S与相邻杂质峰能较好分开,在25.4~508μg.mL-1范围内,峰面积与浓度线性关系良好。3批样品含量分别是99.7%±1.3%,100.4%±1.1%,99.4%±0.96%,总有关物质分别为0.59%~0.97%,样品中水分含量在2.1%~2.3%之间,TFA含量在9.08%~12.76%之间。结论:该方法快速简便,结果准确可靠,可用于Hirulog-S的质量分析。 Objective:To establish an RP-HPLC method for determination of the content of the novel anticoagulant peptide Hirulog-S and the related substances as well as the contents of water and TFA.Methods:Hirulog-S was detected with Zorbax Eclipse XDB-C18 column(150 mm×4.6 mm,5 μm) at 214 nm with the flow rate of 1.0 mL·min-1.The mobile phase A was 0.1%TFA,the mobile phase B was 0.1%ACN,the gradient elution was adopted.The column temperature was 25 ℃.The water content of Hirulog-S was determined by Karl Fischer coulometric titration method,and the TFA content was determined by HPLC method.Results:The calibration curve was linear in the range of 25.4-508 μg·mL^-1.The contents of three batches of products were 99.7%±1.3%,100.4%±1.1% and 99.4%±0.96%,respectively,and total related substances were 0.59%-0.97%,the water content was 2.1%-2.3% and the TFA content was 9.08%-12.76%.Conclusion:The method is reliable,accurate and specific.It can be used for quality analysis of Hirulog-S.
出处 《药物分析杂志》 CAS CSCD 北大核心 2011年第10期1930-1933,共4页 Chinese Journal of Pharmaceutical Analysis
基金 "重大新药创制"科技专项关键技术项目(2009ZX09X503-15)
关键词 抗凝血多肽 Hirulog-S 高效液相色谱 有关物质 水分 三氟乙酸 anticoagulant peptiles Hirulog-S RP-HPLC related substances water TFA
  • 相关文献

参考文献5

  • 1DAI Qiu-yun (戴秋云),HUANG Yuan-yuan (黄园园),DONG Ming-xin (董铭心),et al.Anticoagulated peptides and their usage(一类抗凝血多肽及其用途),China Invention Patent Number:ZL200710120685;International PCT Patent Application Number:PCT/CN2008/001881.
  • 2Pan GX,Wang XM,Huang YH,et al.Development and validation of a LC-MS/MS method for determination of bivalirudin in human plasma:Application to a clinical pharmacokinetic study.J Pharm Biomed Anal,2010,52:105.
  • 3Deeks ED,Curran MP.Bivalirudin:in patients with acute coronary syndromes:planned for urgent or early intervention.Drugs,2008,68(16):2345.
  • 4ChP(中国药典).2005.Vol Ⅲ(三部):186.
  • 5杨小明,赵冬梅,杜秋江,李语如.高效液相色谱法测定比伐卢定中三氟乙酸含量[J].中国生化药物杂志,2010,31(2):126-127. 被引量:14

二级参考文献5

共引文献23

同被引文献23

  • 1Teixeira C, Gomes JR, Gomes P, et al. Viral surface glycopro- teins, gpl20 and glM1, as potential drug targets against HIV-1.Brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug [ J]. Eur J Med Chem, 2011,46(4) :979 -992.
  • 2Naider F, Anglister J. Peptides in the treatment of AIDS [J]. Curt Opin Struct Biol,2009,19(4) :473 -482.
  • 3Mattews T, Salgo M, Greenherg M, et al . Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CIM lymphocytes [J]. Nat Rev, 2004, 3(3) : 215 -225.
  • 4Baldwin CE, Sanders RW, Deng Y, et al. Emergence of a drug- dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor [ J]. J Virol, 2004,78 (22) :12428 - 12437.
  • 5He YX, Chen JW, Lu H, et al. Potent HIV fusion inhibitors against enfuvirtide-resistant HIV-1 strains [ J ]. Proc Natl Acad Sci USA, 2008,105 (42) : 16332 - 16337.
  • 6He YX, Cheng JW, Li JJ, et al. Identification of a critical motif for the human immunodeficiency virus type 1 ( HIV-1 ) gp41 core structure : implications for designing novel anti-HIV fusion inhib- itors [ J ]. J Virol, 2008, 82 ( 13 ) :6349 - 6358.
  • 7Lee MS.Recent progress in the discovery and development of N-type calcium channel modulators for the treatment of pain[J].Prog Med Chem,2014,53:147.
  • 8Pope JE,Deer TR.Ziconotide: a clinical update and pharmacologic review[J].Expert Opin Pharmacol Ther,2013,14(7):957.
  • 9Brady RM,Baell JB,Norton RS.Strategies for the development of conotoxins as new therapeutic leads[J].Mar Drugs,2013,11(7):2293.
  • 10Adams DJ,Berecki G.Mechanisms of conotoxin inhibition of N-type(Ca(v)2.2)calcium channels[J].Biochim Biophys Acta,2013,1828(7):1619.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部